The trend in the price decline should not be put into question for stocks in Bayer over the coming trading sessions given the current chart pattern. Investors should open a short trade and target the € 88.05.
The company has poor fundamentals for a short-term investment strategy.
The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 88.91 EUR in weekly data.
The group's activity appears highly profitable thanks to its outperforming net margins.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The company is in debt and has limited leeway for investment
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
For the past year, analysts have significantly revised downwards their profit estimates.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.